{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-24-000061","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2024-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.335312+00:00","generated_at":"2026-05-31T21:45:56.013341+00:00","sec_items":["1.01","1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akebia terminates Vafseo license with CSL Vifor, sets royalty payments and buy-down option","bullets":["License agreement terminated immediately for business reasons; Akebia regains full U.S. marketing rights for Vafseo.","Akebia to repay $40M working capital fund via quarterly tiered royalties of 8-14% of net sales through May 2028.","Settlement royalties: high single-digit % on net sales up to $450M, mid-single % above; buy-down option from July 2027.","Amended $55M Kreos loan facility to include covenants linked to the termination agreement.","Royalty payments commence July 1, 2025; minimum true-up milestones of $10M, $20M, $40M by 2026-2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-24-000061","json":"https://secwatch.observer/filing/0001517022-24-000061.json","markdown":"https://secwatch.observer/filing/0001517022-24-000061.md","text":"https://secwatch.observer/filing/0001517022-24-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000061/0001517022-24-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000061/akba-20240710.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:45:56.013341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}